<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cardiovasc Med</journal-id><journal-id journal-id-type="iso-abbrev">Front Cardiovasc Med</journal-id><journal-id journal-id-type="pmc-domain-id">2863</journal-id><journal-id journal-id-type="pmc-domain">fcvm</journal-id><journal-id journal-id-type="publisher-id">Front. Cardiovasc. Med.</journal-id><journal-title-group><journal-title>Frontiers in Cardiovascular Medicine</journal-title></journal-title-group><issn pub-type="epub">2297-055X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10508960</article-id><article-id pub-id-type="pmcid-ver">PMC10508960.1</article-id><article-id pub-id-type="pmcaid">10508960</article-id><article-id pub-id-type="pmcaiid">10508960</article-id><article-id pub-id-type="pmid">37731521</article-id><article-id pub-id-type="doi">10.3389/fcvm.2023.1174081</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Cardiovascular Medicine</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Smoking, immunity, and cardiovascular prognosis: a study of plasma IgE concentration in patients with acute myocardial infarction</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="L">Lili</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="an1" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/223762/overview"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhu</surname><given-names initials="Y">Yanrong</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="an1" ref-type="author-notes">
<sup>&#8224;</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meng</surname><given-names initials="X">Xin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1772114/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yifan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1233509/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ren</surname><given-names initials="Q">Qian</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1785879/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="D">Dong</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Chen</surname><given-names initials="Z">Zhong</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/876790/overview"/></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label><addr-line>Department of Cardiology</addr-line>, <institution>Shanghai Sixth People&#8217;s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff><aff id="aff2"><label><sup>2</sup></label><addr-line>Department of Clinical Nutrition</addr-line>, <institution>Shanghai Sixth People&#8217;s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff><aff id="aff3"><label><sup>3</sup></label><addr-line>Department of Cardiology</addr-line>, <institution>Shanghai Sixth People&#8217;s Hospital Fujian</institution>, <addr-line>Fujian</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited by:</bold> Dennis W. T. Nilsen, Stavanger University Hospital, Norway</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Stefan Gross, University Medicine Greifswald, Germany Sawan Jalnapurkar, Gadsden Regional Medical Center, United States Vaiva Lesauskaite, Lithuanian University of Health Sciences, Lithuania</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Zhong Chen <email>zhongchen7498@hotmail.com</email></corresp><fn fn-type="equal" id="an1"><label>
<sup>&#8224;</sup>
</label><p>These authors have contributed equally to this work and share first authorship.</p></fn><fn fn-type="other" id="fn001"><p><bold>Abbreviations</bold> AMI, acute myocardial infarction; CVD, cardiovascular disease; CHD, coronary heart disease; cTNI, cardiac troponin I; ELISA, enzyme-linked immunosorbent assay; hs-CRP, high-sensitivity C-reactive protein; HbA1C, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; MACCE, major adverse cardiac and cerebrovascular events; NT-proBNP, N-terminal pro-brain natriuretic peptide; WBC, white blood cells.</p></fn></author-notes><pub-date pub-type="epub"><day>05</day><month>9</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>10</volume><issue-id pub-id-type="pmc-issue-id">427754</issue-id><elocation-id>1174081</elocation-id><history><date date-type="received"><day>25</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>8</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>20</day><month>09</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-09-21 11:25:17.853"><day>21</day><month>09</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 Zhang, Zhu, Meng, Zhang, Ren, Huang and Chen.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Zhang, Zhu, Meng, Zhang, Ren, Huang and Chen</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcvm-10-1174081.pdf"/><abstract><sec><title>Background</title><p>Immunoglobulin E (IgE) is implicated in the pathogenesis of acute myocardial infarction (AMI), and smokers often exhibit elevated plasma IgE levels. However, it remains uncertain whether the role of smoking in the development and prognosis of AMI is influenced by IgE levels. This study aimed to investigate the potential contribution of IgE in mediating the association between smoking and AMI.</p></sec><sec><title>Methods</title><p>We conducted a prospective study involving 348 consecutive patients with chest discomfort who underwent coronary angiography. Plasma cotinine, an alkaloid present in tobacco, and IgE levels were measured. The patients were followed up for mean 39-months to assess their long-term prognosis based on major adverse cardiac and cerebrovascular events (MACCE).</p></sec><sec><title>Results</title><p>Our findings indicate that patients with AMI had higher plasma levels of cotinine and IgE. Univariate analyses demonstrated a positive association between plasma cotinine (OR<italic toggle="yes">&#8201;</italic>=<italic toggle="yes">&#8201;</italic>1.7, 95% CI: 1.27&#8211;2.26, <italic toggle="yes">P&#8201;</italic>&lt;&#8201;0.001) and IgE (OR<italic toggle="yes">&#8201;</italic>=<italic toggle="yes">&#8201;</italic>2.8, 95% CI: 1.75&#8211;4.39, <italic toggle="yes">P&#8201;</italic>&lt;&#8201;0.001) with AMI. Receiver operating characteristics analyses showed that the combined use of cotinine and IgE (AUC: 0.677) had a larger predictive performance compared to cotinine alone (AUC: 0.639) or IgE alone (AUC: 0.657), although the improvement did not reach statistical significance. Multivariable logistic regression revealed a positive association between plasma cotinine and AMI (OR<italic toggle="yes">&#8201;</italic>=<italic toggle="yes">&#8201;</italic>1.70, 95% CI: 1.04&#8211;2.78, <italic toggle="yes">P&#8201;</italic>=&#8201;0.036). Furthermore, the inclusion of plasma IgE in the regression model led to a decrease in the OR and 95% CI of plasma cotinine (OR<italic toggle="yes">&#8201;</italic>=<italic toggle="yes">&#8201;</italic>1.66, 95% CI: 1.01&#8211;2.73, <italic toggle="yes">P&#8201;</italic>=&#8201;0.048). Process mediation analyses showed a significant indirect effect of plasma cotinine on AMI mediated through increased plasma IgE. Kaplan&#8211;Meier analysis during a mean 39-months follow-up revealed that higher plasma levels of IgE were associated with an increased risk of MACCE following AMI (<italic toggle="yes">P</italic>&#8201;=&#8201;0.047). However, in the context of the COX regression analysis, no significant correlation was observed between IgE, cotinine and AMI.</p></sec><sec><title>Conclusion</title><p>Cotinine exhibits a positive association with AMI, wherein IgE plays a mediating role. Elevated plasma levels of IgE was positively associated with AMI and poor prognosis, which further confirms the adverse role of smoking on the incidence of AMI and prognosis. (Clinical trial registration: ChiCTR2100053000).</p></sec></abstract><kwd-group><kwd>acute myocardial infarction</kwd><kwd>atherosclerosis</kwd><kwd>smoking</kwd><kwd>cotinine</kwd><kwd>immunoglobulin E</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Science and Technology Development</funding-source><award-id award-type="contract" rid="cn001">PKJ2022-Y07</award-id></award-group><award-group><funding-source id="cn002">Shanghai University of Medicine and Health Sciences</funding-source><award-id award-type="contract" rid="cn002">&#160;</award-id></award-group><award-group><funding-source id="cn003">Fujian Provincial Health Commission</funding-source><award-id award-type="contract" rid="cn003">2022CXB015</award-id></award-group><award-group><funding-source id="cn004">Sixth People&#8217;s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</funding-source><award-id award-type="contract" rid="cn004">DY2019005</award-id></award-group></funding-group><funding-group><funding-statement>This study was supported by the Science and Technology Development Fund of Shanghai Pudong New Area (PKJ2022-Y07) and the program of Shanghai University of Medicine and Health Sciences Funds for Teacher Resources Tank (2020) by LZ, Fund from Medical Innovation Project of Fujian Provincial Health Commission (2022CXB015) by ZC, and Hospital Scientific Research Fund of the Sixth People&#8217;s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (DY2019005) by YZ.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="5"/><equation-count count="0"/><ref-count count="54"/><page-count count="0"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Coronary Artery Disease</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Atherosclerotic cardiovascular diseases continue to be the leading cause of morbidity and mortality worldwide (<xref rid="B1" ref-type="bibr">1</xref>). Acute myocardial infarction (AMI) refers to acute myocardial tissue damage resulting from coronary thrombosis and subsequent occlusion of the coronary arteries, usually triggered by the erosion or rupture of unstable atherosclerotic plaques (<xref rid="B2" ref-type="bibr">2</xref>). Smoking, a recognized major risk factor of mortality (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>), significantly contributes to cardiovascular disease (CVD) including AMI. It is associated with various mechanisms such as inflammation, immune response, platelet dysfunction, impaired endothelial function, and increased oxidative stress, which collectively contribute to the development of coronary heart disease (CHD) and AMI (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). However, the precise underlying mechanism through which smoking affects the progression of AMI remains elusive.</p><p>Immunoglobulin E (IgE) plays a crucial role in the pathogenesis of allergic responses by mediating the activation of macrophages, leading to the release of inflammatory molecules such as TNF-&#945; and IFN-&#947; (<xref rid="B7" ref-type="bibr">7</xref>). Experimental studies have indicated an increase in IgE level within atherosclerotic lesions in mice, with observed colocalization alongside plaque macrophages (<xref rid="B7" ref-type="bibr">7</xref>). Notably, IgE deficiency in mice has been shown to confer protection against diet-induced atherosclerosis and foam cell formation (<xref rid="B8" ref-type="bibr">8</xref>). Additionally, IgE has been implicated in promoting the accumulation of neutrophils in atherosclerotic lesion through mast cells activation (<xref rid="B9" ref-type="bibr">9</xref>). Clinical studies have reported an association between plasma IgE level and multi-vessel coronary disease, with elevated IgE levels observed in patients with AMI or unstable angina pectoris (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>).</p><p>Emerging evidence supports the crucial role of inflammation in the pathophysiology of smoking-induced CHD (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Prolonged exposure to cigarette smoke promotes atherosclerosis by triggering the production of pro-inflammatory cytokines and immunoglobulin, such as IL-1&#946; and TNF-&#945; (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). Elevated levels of IgE have been found to be significantly associated with smoking (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). Cotinine, the principal metabolite of nicotine in cigarettes, serves as an objective biomarker for assessing smoking exposure (<xref rid="B18" ref-type="bibr">18</xref>). Recent studies have demonstrated a dose-dependent relationship between cotinine-verified cigarette exposure and total serum IgE levels (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>), suggesting that IgE may serve as a link or mediator between smoking and CHD, including AMI, through the inflammatory immune response. However, limited data are available regarding the correlation between IgE, smoking and AMI, as well as worsened prognosis.</p><p>Given the existing knowledge gaps, our study aimed to evaluate the levels of two specific factors, cotinine and IgE, and investigate the associations among cotinine, IgE, and smoking exposure. Additionally, we conducted a prospective study of AMI patients, to assess the occurrence of major adverse cardiac and cerebrovascular events (MACCE) and explore the potential roles of smoking and IgE. Hypothetically, we propose that cotinine-verified smoking serves as a risk factor for AMI and predicts poor prognosis through an inflammatory response mediated by IgE.</p></sec><sec sec-type="methods" id="s2"><title>Materials and methods</title><sec id="s2a"><title>Study population</title><p>This single center study was conducted from February 2019 to June 2020. We recruited 372 hospitalized patients with suspected CHD for coronary angiography. Patients were excluded if they had previous myocardial infarction within six months (<italic toggle="yes">n</italic>&#8201;=&#8201;2); history of asthma (<italic toggle="yes">n</italic>&#8201;=&#8201;6), malignancies, autoimmune diseases; and treatment with anti-inflammatory drugs (<italic toggle="yes">n</italic>&#8201;=&#8201;5). Patients with advanced liver disease, renal failure, and valvular heart disease were also excluded (<italic toggle="yes">n</italic>&#8201;=&#8201;5). A total of 6 patients with AMI were lost during the 3-year follow-up. The study population included 260 patients with non-AMI (including 92 non-CHD patients and 168 stable CHD patients), and 88 patients diagnosed with AMI (including 55 patients with ST-segment elevation myocardial infarction and 33 patients with non-ST-segment elevation myocardial infarction). AMI patients were followed during a mean period of 39 months and categorized according to levels of IgE and cotinine (<xref rid="s11" ref-type="sec">Supplementary Figure S1</xref>).</p><p>All non-CHD patients had a history of suspicious ischemic symptoms with CVD risk factors. However, they had no evidence of coronary stenosis based on coronary angiography. CHD was diagnosed if coronary angiography revealed at least one significant stenosis (defined as &#8805;50% luminal narrowing in the main coronary arteries or major side branches). Identification of AMI was performed following the recent consensus documents of the American Heart Association and the American College of Cardiology (<xref rid="B21" ref-type="bibr">21</xref>).</p></sec><sec id="s2b"><title>Clinical parameters recorded at baseline</title><p>Patient information was recorded, including age, sex, and cardiovascular risk factors. Smoking status was categorized as smoker and nonsmoker (lifetime smoking history of fewer than 100 cigarettes). Smoking index was calculated using average number of cigarettes smoked per day multiplied by the number of years of smoking. Diagnosis of diabetes was made according to the criteria of the American Diabetes Association (fasting blood glucose concentration of &#8805;7&#8197;mmol/L or the use of insulin or oral hypoglycemic medications) (<xref rid="B22" ref-type="bibr">22</xref>). Hypertension was defined as systolic blood pressure &#8805;140&#8197;mmHg, diastolic blood pressure &#8805;90&#8197;mmHg, or the use of medications prescribed for hypertension (<xref rid="B23" ref-type="bibr">23</xref>). Hyperlipidemia was defined based on total fasting levels of cholesterol &#8805;240&#8197;mg/dl, triglycerides &#8805;200&#8197;mg/dl, high-density lipoprotein cholesterol (HDL-C) &#8804;40&#8197;mg/dl, low-density lipoprotein cholesterol (LDL-C) &#8805;160&#8197;mg/dl, and/or treatment for hyperlipidemia (<xref rid="B24" ref-type="bibr">24</xref>).</p></sec><sec id="s2c"><title>Biochemical measurements</title><p>Blood samples were obtained from all participants while in the recumbent position via antecubital venipuncture at the time of hospital admission. The plasma concentration of high-sensitivity C-reactive protein (hs-CRP), white blood cells (WBC), uric acid, creatinine, alanine aminotransferase (ALT), asparagine transaminase (AST), glycated hemoglobin (HbA1C), N-terminal pro-brain natriuretic peptide (NT-proBNP), cardiac troponin I (cTNI), and lipid profiles, including total cholesterol, triglyceride, LDL-C, and HDL-C, were measured according to standard laboratory protocols. Plasma levels of cotinine and IgE were determined by enzyme-linked immunosorbent assay (ELISA), according to the manufacturer's protocols (CO096D, CALBIOTECH, EI Cajon, CA, USA; SX05002, Senxiong, Shanghai, China).</p></sec><sec id="s2d"><title>Doppler echocardiography</title><p>All participants underwent transthoracic two-dimensional and M-mode echocardiography following recommendations provided by the American Society of Echocardiography (<xref rid="B25" ref-type="bibr">25</xref>). Left ventricular ejection fraction (LVEF) was calculated using the modified Simpson method.</p></sec><sec id="s2e"><title>Follow-up</title><p>Clinical follow-up was conducted using a structured questionnaire of the patient's inpatient medical records, regular outpatient visits, and telephone interview. 88 patients with AMI were followed up for 30&#8211;46 months (average 39 months). Six patients were lost during follow-up (<xref rid="s11" ref-type="sec">Supplementary Figure S1</xref>). The primary clinical endpoint was MACCE during follow-up and defined as all-cause death, target vessel revascularization, myocardial infarction, unstable angina pectoris requiring re-hospitalization, heart failure, stroke, or transient cerebral ischemia. Every 3 months, an interviewer contacted each participant or his/her family member about MACCE. All potential endpoint events were adjudicated by an assessment committee whose members were blind to patients&#8217; characteristics.</p></sec><sec id="s2f"><title>Statistical analysis</title><p>For the continuous variables, data were expressed as the median with inter-quartile ranges. Differences in data were evaluated using Mann&#8211;Whitney <italic toggle="yes">U</italic>-test for comparisons between groups. Categorical variables were summarized as frequencies (percentages) and compared by chi-square test. Partial correlation test was used to assess the correlation between two variables. To determine the association between independent variables and AMI, logistic multivariate regression analysis was performed for indicators with <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 in univariate analysis to calculate odds ratio (OR) and 95% confidence interval (95%Cl). Cotinine, IgE, and NT-proBNP with larger degree of dispersion were analyzed as log-transformed normally distributed variables. Receiver-operating characteristic (ROC) curves were plotted to determine the cotinine and cotinine with IgE for detecting AMI. Using the approach by Hayes and Preacher (<xref rid="B26" ref-type="bibr">26</xref>), the direct and indirect effect sizes of the association between cotinine and incidence of AMI were determined by using IgE as mediators. Kaplan&#8211;Meier survival curves were conducted to estimate the survival status of patients with cotinine and IgE within mean 39 months after AMI. Statistical analysis was performed using SPSS Statistical software, version 22.0 (IBM, Chicago, IL, USA). The mediation analyses were performed using Process version 3.5 added on to SPSS. Two-sided <italic toggle="yes">P</italic>-values of &lt;0.05 were considered statistically significant. The ROC curve and Kaplan&#8211;Meier survival curves were plotted using GraghPad Prism 7.0 (GraphPad Prism Software Inc., San Diego, CA).</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3a"><title>Clinical characteristics of the study participants</title><p>In the current study, we included 348 study participants (209 men and 139 women; mean age 66.64&#8201;&#177;&#8201;11.91 years) of which 260 patients were diagnosed with non-AMI, and 88 patients were diagnosed with AMI. The baseline clinical characteristics in the non-AMI and AMI patients are presented in <xref rid="T1" ref-type="table">Table&#160;1</xref>. Patients in the AMI group were mainly men and had a higher exposure to tobacco smoke (37.69% vs. 48.86%, <italic toggle="yes">P</italic>&#8201;=&#8201;0.03), higher smoking index (0 [0, 400] vs. 20 [0, 600], <italic toggle="yes">P&#8201;</italic>=&#8201;0.01). There were no significant differences in age and history of hypertension, diabetes, or hyperlipidemia between the two groups. At baseline, hs-CRP, WBC, creatinine, cTNI, NT-proBNP among AMI group were significantly higher, whereas HDL-C and LVEF were lower compared with that in the non-AMI group. In addition, the plasma levels of cotinine (1.28 [0.82, 2.75] vs. 2.08 [1.10, 51.30], <italic toggle="yes">P&#8201;</italic>&lt;&#8201;0.001) and IgE (54.97 [27.17, 122.46] vs. 110.63 [53.82, 351.38], <italic toggle="yes">P&#8201;</italic>&lt;&#8201;0.001) were significantly higher in the AMI group.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Clinical characteristics of study patients at baseline.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">non-AMI<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;260)</th><th valign="top" align="center" rowspan="1" colspan="1">AMI<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;88)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Men, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">140 (53.85)</td><td valign="top" align="center" rowspan="1" colspan="1">69 (78.41)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, year</td><td valign="top" align="center" rowspan="1" colspan="1">67 (59, 75)</td><td valign="top" align="center" rowspan="1" colspan="1">67 (57.25, 78)</td><td valign="top" align="center" rowspan="1" colspan="1">0.928</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoking index</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0, 400)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (0, 600)</td><td valign="top" align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">hs-CRP, mg/L</td><td valign="top" align="center" rowspan="1" colspan="1">0.65 (0.53, 2.13)</td><td valign="top" align="center" rowspan="1" colspan="1">2.95 (0.74, 17.34)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">WBC, *10<sup>9</sup>/L</td><td valign="top" align="center" rowspan="1" colspan="1">6.35 (5.28, 7.52)</td><td valign="top" align="center" rowspan="1" colspan="1">8.65 (6.57, 11.65)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TC, mmol/L</td><td valign="top" align="center" rowspan="1" colspan="1">4.37 (3.71, 5.01)</td><td valign="top" align="center" rowspan="1" colspan="1">4.48 (3.71, 5.43)</td><td valign="top" align="center" rowspan="1" colspan="1">0.302</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TG, mmol/L</td><td valign="top" align="center" rowspan="1" colspan="1">1.35 (1.09, 1.84)</td><td valign="top" align="center" rowspan="1" colspan="1">1.54 (1.10, 2.01)</td><td valign="top" align="center" rowspan="1" colspan="1">0.177</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HDL-C, mmol/L</td><td valign="top" align="center" rowspan="1" colspan="1">1.07 (0.92, 1.25)</td><td valign="top" align="center" rowspan="1" colspan="1">1.01 (0.84, 1.14)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LDL-C, mmol/L</td><td valign="top" align="center" rowspan="1" colspan="1">2.67 (2.2, 3.11)</td><td valign="top" align="center" rowspan="1" colspan="1">2.74 (2.28, 3.52)</td><td valign="top" align="center" rowspan="1" colspan="1">0.109</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HbA1c, %</td><td valign="top" align="center" rowspan="1" colspan="1">6.0 (5.6, 6.6)</td><td valign="top" align="center" rowspan="1" colspan="1">6.2 (5.6, 6.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.351</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Serum creatinine, &#956;mol/L</td><td valign="top" align="center" rowspan="1" colspan="1">69 (55.5, 80)</td><td valign="top" align="center" rowspan="1" colspan="1">78 (63, 92)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">cTNI, ng/ml</td><td valign="top" align="center" rowspan="1" colspan="1">3.0 (0.02, 5.41)</td><td valign="top" align="center" rowspan="1" colspan="1">4.3 (1.10, 13.77)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NT-proBNP, pg/ml</td><td valign="top" align="center" rowspan="1" colspan="1">116.5 (45.60, 503.53)</td><td valign="top" align="center" rowspan="1" colspan="1">1101 (188.25, 3331.50)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LVEF, %</td><td valign="top" align="center" rowspan="1" colspan="1">60 (57, 64)</td><td valign="top" align="center" rowspan="1" colspan="1">58 (55, 61)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cotinine, ng/ml</td><td valign="top" align="center" rowspan="1" colspan="1">1.28 (0.82, 2.75)</td><td valign="top" align="center" rowspan="1" colspan="1">2.08 (1.10, 51.30)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IgE, ng/ml</td><td valign="top" align="center" rowspan="1" colspan="1">54.97 (27.17, 122.46)</td><td valign="top" align="center" rowspan="1" colspan="1">110.63 (53.82, 351.38)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" colspan="4" rowspan="1">History, <italic toggle="yes">n</italic> (%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Current smoking</td><td valign="top" align="center" rowspan="1" colspan="1">98 (37.69)</td><td valign="top" align="center" rowspan="1" colspan="1">47 (53.41)</td><td valign="top" align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypertension</td><td valign="top" align="center" rowspan="1" colspan="1">177 (68.08)</td><td valign="top" align="center" rowspan="1" colspan="1">51 (57.95)</td><td valign="top" align="center" rowspan="1" colspan="1">0.093</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diabetes</td><td valign="top" align="center" rowspan="1" colspan="1">61 (23.46)</td><td valign="top" align="center" rowspan="1" colspan="1">25 (28.41)</td><td valign="top" align="center" rowspan="1" colspan="1">0.391</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hyperlipidemia</td><td valign="top" align="center" rowspan="1" colspan="1">20 (7.69)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (12.50)</td><td valign="top" align="center" rowspan="1" colspan="1">0.194</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1"><p>AMI, acute myocardial infarction; hs-CRP, high sensitivity C-reactive protein; WBC, white blood cells; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HbA1c, glycated hemoglobin; cTNI, cardiac troponin I; NT-proBNP, N-terminal pro-brain natriuretic peptide; LVEF, left ventricular ejection fraction.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>The characteristics of cotinine and IgE in patients with a history of smoking</title><p>Because cotinine is the main metabolite of nicotine and smoking might induce the elevation of plasma IgE, we compared the difference of cotinine, IgE, and other parameters between smokers and non-smokers (<xref rid="s11" ref-type="sec">Supplementary Table S1</xref>). Compared to non-smokers, smokers were younger (<italic toggle="yes">P&#8201;</italic>&lt;&#8201;0.001), had higher plasma creatinine (<italic toggle="yes">P&#8201;</italic>&lt;&#8201;0.001), cotinine (12.27 [1.33, 67.09] vs. 1.07 [0.66, 1.65], <italic toggle="yes">P&#8201;</italic>&lt;&#8201;0.001) and IgE (87.37 [38.62, 288.78] vs. 55.09 [26.20, 113.06], <italic toggle="yes">P&#8201;</italic>&lt;&#8201;0.001) (<xref rid="F1" ref-type="fig">Figure&#160;1</xref>). Furthermore, we investigated the correlations between plasma cotinine, and plasma IgE levels. After adjusting for hs-CRP, positively week correlations were found between plasma cotinine and plasma IgE levels (<italic toggle="yes">r</italic>&#8201;=&#8201;0.174, <italic toggle="yes">P&#8201;</italic>=&#8201;0.002).</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>The distribution nof cotinine and IgE in non-smokers vs. smokers. (<bold>A</bold>) Shows plasma level of cotinine, and (<bold>B</bold>) shows IgE concentration in plasma.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcvm-10-1174081-g001.jpg"/></fig></sec><sec id="s3c"><title>IgE as a mediator of the association between cotinine and AMI</title><p>To assess the association between cotinine and IgE and its effect on the risk of AMI, we used univariate logistic regression analyses. The results indicated a positive association between plasma cotinine (log 10) (OR&#8201;=&#8201;1.7, 95% CI: 1.27&#8211;2.26, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) and AMI. Similarly, there was a positive association between plasma IgE (log 10) (OR&#8201;=&#8201;2.8, 95% CI: 1.75&#8211;4.39, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) and AMI. To investigate whether cotinine and IgE could provide better prediction of AMI compared with plasma cotinine alone, we performed ROC analyses. The results showed that the area under the curve (AUC) for IgE was 0.657 (95% CI: 0.590&#8211;0.725) (<xref rid="s11" ref-type="sec">Supplementary Figure S1</xref>). As shown in <xref rid="F2" ref-type="fig">Figure&#160;2</xref>, AUC for cotinine was 0.639 (95% CI: 0.571&#8211;0.708), whereas AUC for cotinine combined with IgE was 0.677 (95% CI: 0.608&#8211;0.745). These data indicated that the combined AUROC of cotinine and IgE was higher than that of cotinine alone, although the difference did not reach statistical significance (<xref rid="T2" ref-type="table">Table&#160;2</xref>).</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><p>Receiver operating characteristics analyses using cotinine (log 10, ng/ml) with or without IgE (log 10, ng/ml) as predictors of myocardial infarction.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcvm-10-1174081-g002.jpg"/></fig><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>AUROC differences between cotinine&#8201;+&#8201;IgE with cotinine and IgE alone.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">A</th><th valign="top" align="center" rowspan="1" colspan="1">B</th><th valign="top" align="center" rowspan="1" colspan="1">AUROC<break/>(A)</th><th valign="top" align="center" rowspan="1" colspan="1">AUROC<break/>(B)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">IgE (log 10, ng/ml)</td><td valign="top" align="left" rowspan="1" colspan="1">Cotinine (log 10, ng/ml)</td><td valign="top" align="center" rowspan="1" colspan="1">0.657</td><td valign="top" align="center" rowspan="1" colspan="1">0.639</td><td valign="top" align="center" rowspan="1" colspan="1">0.560</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cotinine (log 10, ng/ml)</td><td valign="top" align="left" rowspan="1" colspan="1">Cotinine&#8201;+&#8201;IgE</td><td valign="top" align="center" rowspan="1" colspan="1">0.639</td><td valign="top" align="center" rowspan="1" colspan="1">0.677</td><td valign="top" align="center" rowspan="1" colspan="1">0.320</td></tr></tbody></table></table-wrap><p>As smoking exposure increases plasma cotinine and activates inflammation and expression of IgE, we investigated whether the elevation of IgE might explain the association between cotinine and AMI by analyzing the association between plasma cotinine (log 10) and incidence of AMI with or without IgE (log 10). By univariate analyses, we confirmed that sex, WBC, HDL-C, hs-CRP, LVEF, cTNI, and NT-proBNP (log 10) were significantly positively associated with AMI (<xref rid="s11" ref-type="sec">Supplementary Table S2</xref>). In multivariable analyses, only hs-CRP, WBC, cTNI, NT-proBNP (log 10), and cotinine (log 10) (OR&#8201;=&#8201;1.70, 95% CI: 1.04&#8211;2.78, <italic toggle="yes">P&#8201;</italic>=&#8201;0.036) remained statistically significant. When IgE (log 10) was added into the multivariable analyses model, a decrease in the association of cotinine (OR&#8201;=&#8201;1.66, 95% CI: 1.01&#8211;2.73, <italic toggle="yes">P&#8201;</italic>=&#8201;0.048) with incident AMI was observed (<xref rid="T3" ref-type="table">Table&#160;3</xref>). However, there is no significant association between IgE (log 10) and AMI.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Logistic regression analysis of the correlation between cotinine and AMI with or without IgE.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="center" colspan="2" rowspan="1">Model 1 (<italic toggle="yes">n</italic>&#8201;=&#8201;348)</th><th valign="top" align="center" colspan="2" rowspan="1">Model 2 (<italic toggle="yes">n</italic>&#8201;=&#8201;348)</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th valign="top" align="center" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">0.40 (0.16&#8211;1.02)</td><td valign="top" align="center" rowspan="1" colspan="1">0.056</td><td valign="top" align="center" rowspan="1" colspan="1">0.40 (0.15&#8211;1.02)</td><td valign="top" align="center" rowspan="1" colspan="1">0.054</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">hs-CRP</td><td valign="top" align="center" rowspan="1" colspan="1">1.05 (1.01&#8211;1.09)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">1.05 (1.00&#8211;1.09)</td><td valign="top" align="center" rowspan="1" colspan="1">0.043</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">WBC</td><td valign="top" align="center" rowspan="1" colspan="1">1.61 (1.32&#8211;1.96)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">1.60 (1.32&#8211;1.95)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HDL-C</td><td valign="top" align="center" rowspan="1" colspan="1">0.40 (0.08&#8211;1.97)</td><td valign="top" align="center" rowspan="1" colspan="1">0.261</td><td valign="top" align="center" rowspan="1" colspan="1">0.41 (0.08&#8211;1.99)</td><td valign="top" align="center" rowspan="1" colspan="1">0.267</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Serum creatinine</td><td valign="top" align="center" rowspan="1" colspan="1">1.01 (0.99&#8211;1.03)</td><td valign="top" align="center" rowspan="1" colspan="1">0.442</td><td valign="top" align="center" rowspan="1" colspan="1">1.01 (0.99&#8211;1.02)</td><td valign="top" align="center" rowspan="1" colspan="1">0.474</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LVEF</td><td valign="top" align="center" rowspan="1" colspan="1">0.96 (0.90&#8211;1.03)</td><td valign="top" align="center" rowspan="1" colspan="1">0.963</td><td valign="top" align="center" rowspan="1" colspan="1">0.96 (0.90&#8211;1.03)</td><td valign="top" align="center" rowspan="1" colspan="1">0.285</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">cTNI</td><td valign="top" align="center" rowspan="1" colspan="1">1.15 (1.06&#8211;1.26)</td><td valign="top" align="center" rowspan="1" colspan="1">0.001</td><td valign="top" align="center" rowspan="1" colspan="1">1.15 (1.05&#8211;1.25)</td><td valign="top" align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NT-proBNP (log 10)</td><td valign="top" align="center" rowspan="1" colspan="1">2.82 (1.48&#8211;5.36)</td><td valign="top" align="center" rowspan="1" colspan="1">0.002</td><td valign="top" align="center" rowspan="1" colspan="1">2.83 (1.48&#8211;5.41)</td><td valign="top" align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cotinine (log 10)</td><td valign="top" align="center" rowspan="1" colspan="1">1.70 (1.04&#8211;2.78)</td><td valign="top" align="center" rowspan="1" colspan="1">0.036</td><td valign="top" align="center" rowspan="1" colspan="1">1.66 (1.01&#8211;2.73)</td><td valign="top" align="center" rowspan="1" colspan="1">0.048</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IgE (log 10)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1.24 (0.62&#8211;2.51)</td><td valign="top" align="center" rowspan="1" colspan="1">0.543</td></tr></tbody></table><table-wrap-foot><fn id="table-fn2"><p>hs-CRP, high sensitivity C-reactive protein; WBC, white blood cell; HDL-C, high-density lipoprotein cholesterol; cTNI, cardiac troponin I; NT-proBNP, N-terminal pro-brain natriuretic peptide; LVEF, left ventricular ejection fraction, and OR, odds ratio.</p></fn></table-wrap-foot></table-wrap><p>To evaluate whether the reduced odds ratio is indeed due to increased IgE, we further performed mediation analyses using the statistical approach by Hayes and Preacher (<xref rid="B26" ref-type="bibr">26</xref>). By this method, we could estimate the significance and size of indirect effect of cotinine on AMI carried by elevated plasma IgE. As shown in <xref rid="T4" ref-type="table">Table&#160;4</xref>, the direct effect of plasma cotinine on AMI was 0.34 (95% CI: 0.04&#8211;0.65), whereas its indirect effect was 0.08 (95% CI: 0.02&#8211;0.17). The proportion mediated by IgE in the effect size of cotinine on AMI was 0.24.</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>Direct and indirect effect sizes of cotinine for AMI as mediated by IgE.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="2" colspan="1"/><th valign="top" align="center" rowspan="2" colspan="1">Effect</th><th valign="top" align="center" rowspan="2" colspan="1">SE</th><th valign="top" align="center" rowspan="2" colspan="1">
<italic toggle="yes">P</italic>
</th><th valign="top" align="center" colspan="2" rowspan="1">95% CI</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">LLCI</th><th valign="top" align="center" rowspan="1" colspan="1">ULCI</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Direct effect</td><td valign="top" align="center" rowspan="1" colspan="1">0.343</td><td valign="top" align="center" rowspan="1" colspan="1">0.154</td><td valign="top" align="center" rowspan="1" colspan="1">0.026</td><td valign="top" align="center" rowspan="1" colspan="1">0.041</td><td valign="top" align="center" rowspan="1" colspan="1">0.645</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Indirect effect</td><td valign="top" align="center" rowspan="1" colspan="1">0.083</td><td valign="top" align="center" rowspan="1" colspan="1">0.039</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">0.018</td><td valign="top" align="center" rowspan="1" colspan="1">0.170</td></tr></tbody></table><table-wrap-foot><fn id="table-fn3"><p>LLCI, low limit confidence interval; ULCI, upper limit confidence interval.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3d"><title>Survival analysis</title><p>After a median follow-up of 39 months, a total of 48 (54.5%) AMI patients suffered from MACCE. Patients with AMI were divided into two groups based on MACCE, namely MACCE (+) and MACCE (&#8722;) groups. We compared the baseline characteristics between the two groups, and found that patients in the MACCE (&#8722;) group were significantly younger than those in the MACCE (+) group (61.05&#8201;&#177;&#8201;13.93 vs. 70.42&#8201;&#177;&#8201;12.21, <italic toggle="yes">P&#8201;</italic>=&#8201;0.001), and plasma IgE (84.88 [38.09, 227.55] vs. 194.49 [67.76, 417.71], <italic toggle="yes">P&#8201;</italic>=&#8201;0.048), and HbA1c (6.0 [5.30, 6.30] vs. 6.40 [5.90, 7.70], <italic toggle="yes">P&#8201;</italic>=&#8201;0.002) in MACCE (+) group were higher compared with that in the MACCE (&#8722;) group (<xref rid="F3" ref-type="fig">Figure&#160;3A</xref>). However, no significant differences occurred in plasma cotinine (2.88 [1.14, 51.24] vs. 1.89 [1.10, 54.30], <italic toggle="yes">P&#8201;</italic>=&#8201;0.798) and other clinical markers (<xref rid="s11" ref-type="sec">Supplementary Table S3</xref>).</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3</label><caption><p>The characteristic of plasma IgE concentration during mean 39-months follow-up. (<bold>A</bold>) Distribution of plasma IgE in MACCE (&#8722;) vs. MACCE (+). (<bold>B</bold>) Kaplan&#8211;Meier survival by elevated plasma IgE.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcvm-10-1174081-g003.jpg"/></fig><p>Furthermore, patients with AMI were divided into high (Q3&#8211;Q4) and low (Q1&#8211;Q2) level groups based on plasma cotinine and IgE quartiles. The Kaplan&#8211;Meier curve depicted the follow-up without MACCE (MACCE-free) survival by comparing high and low levels of cotinine and IgE in AMI patients, followed by comparison of survival curves using the log-rank test. As presented in <xref rid="F3" ref-type="fig">Figure&#160;3B</xref>, Kaplan&#8211;Meier survival curves showed that AMI patients with higher plasma IgE had reduced MACCE-free survival time (<italic toggle="yes">P&#8201;</italic>=&#8201;0.047). However, no difference was found for survival time between high and low levels of plasma cotinine (<italic toggle="yes">P&#8201;</italic>=&#8201;0.62, <xref rid="s11" ref-type="sec">Supplementary Figure S2</xref>).</p><p>We further conducted multivariate COX proportional hazard regression analysis to identify risk factors for MACCE. However, after adjustment for confounders, the results showed that only age was significantly associated with MACCE, while IgE and cotinine did not show any significant correlation with MACCE (<xref rid="T5" ref-type="table">Table&#160;5</xref>).</p><table-wrap position="float" id="T5" orientation="portrait"><label>Table 5</label><caption><p>Multivariate cox proportional hazards regression analyses for the risk factors of MACCE during follow-up among patients with AMI.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">HR</th><th valign="top" align="center" rowspan="1" colspan="1">95% CI</th><th valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, year</td><td valign="top" align="center" rowspan="1" colspan="1">1.04</td><td valign="top" align="center" rowspan="1" colspan="1">1.01&#8211;1.07</td><td valign="top" align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cotinine (log 10)</td><td valign="top" align="center" rowspan="1" colspan="1">1.22</td><td valign="top" align="center" rowspan="1" colspan="1">0.77&#8211;1.96</td><td valign="top" align="center" rowspan="1" colspan="1">0.399</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IgE (log 10)</td><td valign="top" align="center" rowspan="1" colspan="1">1.53</td><td valign="top" align="center" rowspan="1" colspan="1">0.84&#8211;2.81</td><td valign="top" align="center" rowspan="1" colspan="1">0.167</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>In the present study, we observed a significant elevation in the concentrations of both plasma cotinine and IgE in patients with AMI. Both elevations in plasma cotinine and IgE were associated with AMI, and the predictive performance of cotinine combined with IgE was better than that of either alone. Importantly, our data suggest that the impact of cotinine on AMI is partly mediated by an increase in plasma IgE concentration. Additionally, plasma IgE, not cotinine, was significantly associated with MACCE events within a mean 39-months follow-up after AMI.</p><p>Elevated plasma concentration of IgE has been investigated as a potential risk factor for CVDs (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B27" ref-type="bibr">27</xref>). Meanwhile, studies have shown that circulating IgE levels in patients with atherosclerosis are associated with plaque instability and severity of CHD (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B10" ref-type="bibr">10</xref>). Immunologic mechanisms play a major role in the pathogenesis of coronary plaque instability, leading to AMI (<xref rid="B28" ref-type="bibr">28</xref>). IgE, as an important regulator of allergic reactions, binds to high and low affinity Fc&#949;RI and Fc&#949;RII receptors on the mast and macrophage cell surface. Research by Shi et al. (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>) revealed that IgE could promote the formation of atherosclerosis by stimulating cell apoptosis and cytokine expression, influencing macrophage polarization, and facilitating foam cell formation. Consistent with these findings, our study demonstrates a significant increase in plasma IgE levels in patients with AMI, suggesting its potential as a predictive marker for AMI based on AUC analyses.</p><p>Smoking disturbs immune homeostasis by modulating immune-regulatory activities, leading to various pathogenic mechanisms, including increased oxidative stress, reactive oxygen species (ROS), and the activation of T and B cell proliferation, which subsequently enhance the expression of pro-inflammatory markers (<xref rid="B29" ref-type="bibr">29</xref>). Studies have consistently reported elevated levels of circulating IgE in smokers (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Furthermore, previous research has demonstrated that IgE plays a role in amplifying the immune-inflammatory response associated with smoking. It can induce neutrophil activation, mast cell activation, further exacerbating the inflammatory and cytokine cascade (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>). In this study, we employed plasma cotinine measurement, widely recognized as a reliable biomarker of tobacco exposure (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B34" ref-type="bibr">34</xref>), to ascertain the smoking status and self-reported cigarettes per day. Consistent with previous findings (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>), our data revealed higher plasma cotinine and IgE levels in patients with a smoking history. Additionally, we identified an intrinsic association between cotinine and IgE levels, suggesting that smoking may partially induce an inflammatory response through plasma IgE. Notably, as the major metabolite of nicotine, cotinine offers a more accurate estimation of smoking status.</p><p>A higher proportion of patients with AMI were found to have a history of smoking and elevated plasma cotinine levels, which is consistent with previous reports (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>). Based on these findings, we further investigated the potential mediation effect of IgE in the association between plasma cotinine and AMI using mediation analyses. Our data revealed that the association between plasma cotinine and AMI was markedly attenuated when adjusting for plasma IgE concentration. Specifically, the positive association between plasma cotinine and AMI decreased from 1.70 to 1.66 after incorporating IgE into the model, suggesting that IgE acts as a mediator in the association between plasma cotinine and AMI. Through Hayes and Preacher's mediation analysis (<xref rid="B26" ref-type="bibr">26</xref>), we estimated that approximately 24% of the effect of cotinine on AMI was mediated by IgE. These findings confirmed that the observed positive correlation between AMI and smoking, as indicated by plasma cotinine, is partly mediated by the elevation of plasma IgE concentration.</p><p>Despite extensive clinical, experimental and epidemiological investigations on the association between smoking and AMI, the underlying mechanisms are still subject to ongoing scrutiny (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). Smoking has been shown to activate neutrophils, T and B lymphocytes, and induce endotoxin exposure, all of which can contribute to elevated IgE levels and subsequent inflammatory response (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>). Elevated IgE has been implicated in the pathogenesis of atherosclerosis and AMI through its activation of macrophages and mast cells, leading to cytokine secretion, foam cell formation, and the expression of IL-17/22 (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>) (<xref rid="F4" ref-type="fig">Figure&#160;4</xref>). However, the specific mechanism by which smoking induces elevated IgE levels and exacerbates atherosclerosis and plaque instability requires further investigation.</p><fig position="float" id="F4" orientation="portrait"><label>Figure 4</label><caption><p>IgE acts as a mediator in the link between smoking and myocardial infarction. Smoking causes to the release of cotinine into the plasma, subsequently activating the T and B lymphocytes, resulting in the release of IgE. Within the intima, IgE activates macrophages and mast cells through Fc&#949;RI and Fc&#949;RII receptors. Both macrophages and mast cells contribute to the formation of foam cells and the instability of coronary atheromatous plaques.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcvm-10-1174081-g004.jpg"/></fig><p>Smoking is recognized as a significant determinant of cardiovascular morbidity and mortality, particularly among men worldwide and women in developed countries (<xref rid="B43" ref-type="bibr">43</xref>). The term &#8220;smoker's paradox&#8221; has been used to describe the controversial notion that smoking might improve cardiovascular outcomes post-AMI (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>). However, conflicting evidence has emerged, refuting these paradoxical findings (<xref rid="B46" ref-type="bibr">46</xref>&#8211;<xref rid="B48" ref-type="bibr">48</xref>). Our data, assessed through Kaplan&#8211;Meier analysis, indicate no difference in plasma cotinine levels between patients with or without MACCE. Furthermore, in our Cox regression analysis, both cotinine and IgE did not show any significant correlation with MACCE events after AMI. These findings may be influenced by various factors, including the cross-sectional nature of our study, which limited our ability to establish causation between plasma cotinine, plasma IgE and AMI. It is noteworthy that most patients tended to quit smoking after experiencing an AMI event, and some smokers had their infarction at an earlier age compared to non-smokers. Importantly, our study reveals that AMI patients with high plasma IgE concentration exhibit a higher incidence (<italic toggle="yes">P&#8201;</italic>=&#8201;0.048) of MACCE. Both AMI and smoking can trigger immune-inflammatory responses that lead to IgE release. Furthermore, IgE not only plays a role in the acute phase of AMI, but also contributes to the process of ventricular remodeling (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B49" ref-type="bibr">49</xref>). Consistent with our findings, several studies have independently associated IgE with cardiovascular events and identified it as a potential risk factor for increased cardiovascular mortality (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>). Therefore, our findings suggest that IgE may serve as a mediator in the association between smoking and AMI. Furthermore, elevated IgE levels could potentially be a risk factor for MACCE following AMI. IgE might also serve as a valuable marker for assessing the efficacy of anti-inflammatory interventions. Additionally, targeting IgE could offer an alternative therapeutic approach to prevent smoking induced AMI and improve subsequent prognosis. Our study also identified several clinical variables that were positively associated with AMI, including hs-CRP, WBC, cTNI, and NT-proBNP, consistent with findings from previous studies (<xref rid="B51" ref-type="bibr">51</xref>&#8211;<xref rid="B54" ref-type="bibr">54</xref>). While hs-CRP and WBC partially reflect the inflammatory response during AMI occurrence, we investigated the potential role of IgE as an immune-inflammatory marker in this context. Surprisingly, our logistic regression analysis demonstrated that the inclusion of IgE (log 10) did not result in significant changes in the OR values of hs-CRP and WBC. This finding suggests that IgE may not play a substantial role in the inflammatory response associated with hs-CRP and WBC in the context of AMI. On the other hand, cTNI and NT-proBNP, as direct indicators of myocardial ischemic necrosis, have been extensively studied and have consistently shown a strong correlation with AMI (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>). The robust association of these biomarkers with AMI further reinforces the reliability of our data.</p><p>These are several limitations to the present study. Firstly, the cross-sectional nature of our analysis limits our ability to establish causation between plasma cotinine, plasma IgE and AMI. It is advisable to consider the temporal relationship between plasma cotinine and IgE levels in future analyses. Additionally, it is important to assess the smoking status after AMI to better understand its impact on the observed associations. Secondly, the relatively small sample size and single-center recruitment of participants may affect the generalizability of our findings. However, our study benefits from a well-designed research protocol and utilizes established methods, with the advantage of comprehensive evaluation through coronary angiography, laboratory testing, and clinical assessment, ensuring enrollment of confirmed AMI and non-AMI subjects. Although AMI can be clinically classified into ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), both conditions are considered acute coronary syndromes characterized by acute myocardial injury due to coronary artery ischemia. As IgE is involved in acute inflammatory responses, it is plausible that there may be no significant differences between the two groups regarding acute myocardial injury and inflammatory response. Finally, the cotinine-based correction introduces potential bias as cotinine levels can be influenced by other factors, which may in turn affect a minority of the participants. Further studies with larger sample sizes are warranted to validate our findings and elucidate the underlying biological mechanisms.</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusion</title><p>Our study demonstrates that elevated plasma cotinine and IgE concentrations are associated with AMI. IgE may partially explain the increased incidence of AMI in smokers as indicated by cotinine measurement. Additionally, IgE shows promise as a predictor of MACCE after AMI. These findings support the role of elevated IgE as a mediator in the pathogenesis of smoking-related cardiovascular disease. Targeting the IgE pathway and its associated inflammatory mechanisms may hold promise for preventing fatal cardiovascular events among smokers.</p></sec></body><back><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>This study involving humans were approved by the Ethics Committee of Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Shanghai, China) and complies with the Declaration of Helsinki. The study was conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>LZ designed and conducted the research study, performed data management, data analysis and wrote the manuscript. YZhu conducted the research study, performed data management, data analysis, and manuscript revision. XM, YZ and QR performed data management and edited the figures and article format. DH performed data analysis and provided substantial assistance in refining and revising manuscript. ZC made key revisions to the article. All authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s11"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fcvm.2023.1174081/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fcvm.2023.1174081/full#supplementary-material</ext-link></p><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Datasheet1.docx" id="d95e1258" position="anchor" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><article-title>Global, regional, and national age-sex specific mortality for 264 causes of death, 1980&#8211;2016: a systematic analysis for the global burden of disease study 2016</article-title>. <source>Lancet (London, England)</source>. (<year>2017</year>) <volume>390</volume>(<issue>10100</issue>):<fpage>1151</fpage>&#8211;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(17)32152-9</pub-id><pub-id pub-id-type="pmid">28919116</pub-id><pub-id pub-id-type="pmcid">PMC5605883</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Libby</surname><given-names>P</given-names></name><name name-style="western"><surname>Pasterkamp</surname><given-names>G</given-names></name><name name-style="western"><surname>Crea</surname><given-names>F</given-names></name><name name-style="western"><surname>Jang</surname><given-names>IK</given-names></name></person-group>. <article-title>Reassessing the mechanisms of acute coronary syndromes</article-title>. <source>Circ Res</source>. (<year>2019</year>) <volume>124</volume>(<issue>1</issue>):<fpage>150</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.311098</pub-id><pub-id pub-id-type="pmid">30605419</pub-id><pub-id pub-id-type="pmcid">PMC6447371</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ezzati</surname><given-names>M</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>AD</given-names></name></person-group>. <article-title>Estimates of global mortality attributable to smoking in 2000</article-title>. <source>Lancet (London, England)</source>. (<year>2003</year>) <volume>362</volume>(<issue>9387</issue>):<fpage>847</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)14338-3</pub-id><pub-id pub-id-type="pmid">13678970</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Rifai</surname><given-names>M</given-names></name><name name-style="western"><surname>Blaha</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Nambi</surname><given-names>V</given-names></name><name name-style="western"><surname>Shea</surname><given-names>SJC</given-names></name><name name-style="western"><surname>Michos</surname><given-names>ED</given-names></name><name name-style="western"><surname>Blumenthal</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Determinants of incident atherosclerotic cardiovascular disease events among those with absent coronary artery calcium: multi-ethnic study of atherosclerosis</article-title>. <source>Circulation</source>. (<year>2022</year>) <volume>145</volume>(<issue>4</issue>):<fpage>259</fpage>&#8211;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.121.056705</pub-id><pub-id pub-id-type="pmid">34879218</pub-id><pub-id pub-id-type="pmcid">PMC8792296</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McEvoy</surname><given-names>JW</given-names></name><name name-style="western"><surname>Nasir</surname><given-names>K</given-names></name><name name-style="western"><surname>DeFilippis</surname><given-names>AP</given-names></name><name name-style="western"><surname>Lima</surname><given-names>JA</given-names></name><name name-style="western"><surname>Bluemke</surname><given-names>DA</given-names></name><name name-style="western"><surname>Hundley</surname><given-names>WG</given-names></name><etal/></person-group><article-title>Relationship of cigarette smoking with inflammation and subclinical vascular disease: the multi-ethnic study of atherosclerosis</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2015</year>) <volume>35</volume>(<issue>4</issue>):<fpage>1002</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.114.304960</pub-id><pub-id pub-id-type="pmid">25745060</pub-id><pub-id pub-id-type="pmcid">PMC4484586</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>KW</given-names></name><name name-style="western"><surname>Park</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>KH</given-names></name><name name-style="western"><surname>Kang</surname><given-names>SH</given-names></name><name name-style="western"><surname>Oh</surname><given-names>IY</given-names></name><name name-style="western"><surname>Yang</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Enhanced clopidogrel responsiveness in smokers: smokers&#8217; paradox is dependent on cytochrome P450 CYP1A2 status</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2011</year>) <volume>31</volume>(<issue>3</issue>):<fpage>665</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.110.217182</pub-id><pub-id pub-id-type="pmid">21148426</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>MX</given-names></name><name name-style="western"><surname>Alanne-Kinnunen</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JA</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Ige stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in apoe-/-mice</article-title>. <source>J Clin Invest</source>. (<year>2011</year>) <volume>121</volume>(<issue>9</issue>):<fpage>3564</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1172/JCI46028</pub-id><pub-id pub-id-type="pmid">21821913</pub-id><pub-id pub-id-type="pmcid">PMC3163955</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Ige contributes to atherosclerosis and obesity by affecting macrophage polarization, macrophage protein network, and foam cell formation</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2020</year>) <volume>40</volume>(<issue>3</issue>):<fpage>597</fpage>&#8211;<lpage>610</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.119.313744</pub-id><pub-id pub-id-type="pmid">31996021</pub-id><pub-id pub-id-type="pmcid">PMC7047522</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wezel</surname><given-names>A</given-names></name><name name-style="western"><surname>Lagraauw</surname><given-names>HM</given-names></name><name name-style="western"><surname>van der Velden</surname><given-names>D</given-names></name><name name-style="western"><surname>de Jager</surname><given-names>SC</given-names></name><name name-style="western"><surname>Quax</surname><given-names>PH</given-names></name><name name-style="western"><surname>Kuiper</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mast cells mediate neutrophil recruitment during atherosclerotic plaque progression</article-title>. <source>Atherosclerosis</source>. (<year>2015</year>) <volume>241</volume>(<issue>2</issue>):<fpage>289</fpage>&#8211;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.05.028</pub-id><pub-id pub-id-type="pmid">26062988</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Serum IgE levels are associated with coronary artery disease severity</article-title>. <source>Atherosclerosis</source>. (<year>2016</year>) <volume>251</volume>:<fpage>355</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2016.05.020</pub-id><pub-id pub-id-type="pmid">27211478</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinkiewicz</surname><given-names>W</given-names></name><name name-style="western"><surname>B&#322;azejewski</surname><given-names>J</given-names></name><name name-style="western"><surname>Bujak</surname><given-names>R</given-names></name><name name-style="western"><surname>Kubica</surname><given-names>J</given-names></name><name name-style="western"><surname>Dudziak</surname><given-names>J</given-names></name></person-group>. <article-title>Immunoglobulin E in patients with ischemic heart disease</article-title>. <source>Cardiol J</source>. (<year>2008</year>) <volume>15</volume>(<issue>2</issue>):<fpage>122</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.5603/cj.21621</pub-id><pub-id pub-id-type="pmid">18651396</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laan</surname><given-names>M</given-names></name><name name-style="western"><surname>Bozinovski</surname><given-names>S</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>GP</given-names></name></person-group>. <article-title>Cigarette smoke inhibits lipopolysaccharide-induced production of inflammatory cytokines by suppressing the activation of activator protein-1 in bronchial epithelial cells</article-title>. <source>J Immunol</source>. (<year>2004</year>) <volume>173</volume>(<issue>6</issue>):<fpage>4164</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.173.6.4164</pub-id><pub-id pub-id-type="pmid">15356167</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walters</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Paul-Clark</surname><given-names>MJ</given-names></name><name name-style="western"><surname>McMaster</surname><given-names>SK</given-names></name><name name-style="western"><surname>Ito</surname><given-names>K</given-names></name><name name-style="western"><surname>Adcock</surname><given-names>IM</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>JA</given-names></name></person-group>. <article-title>Cigarette smoke activates human monocytes by an oxidant-AP-1 signaling pathway: implications for steroid resistance</article-title>. <source>Mol Pharmacol</source>. (<year>2005</year>) <volume>68</volume>(<issue>5</issue>):<fpage>1343</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1124/mol.105.012591</pub-id><pub-id pub-id-type="pmid">16061772</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lau</surname><given-names>PP</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Merched</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>AL</given-names></name><name name-style="western"><surname>Ko</surname><given-names>KW</given-names></name><name name-style="western"><surname>Chan</surname><given-names>L</given-names></name></person-group>. <article-title>Nicotine induces proinflammatory responses in macrophages and the aorta leading to acceleration of atherosclerosis in low-density lipoprotein receptor(-/-) mice</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2006</year>) <volume>26</volume>(<issue>1</issue>):<fpage>143</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1161/01.ATV.0000193510.19000.10</pub-id><pub-id pub-id-type="pmid">16254210</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>F</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Gong</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title><italic toggle="yes">&#945;</italic>1-nAchR-Mediated signaling through lipid raft is required for nicotine-induced NLRP3 inflammasome activation and nicotine-accelerated atherosclerosis</article-title>. <source>Front Cell Dev Biol</source>. (<year>2021</year>) <volume>9</volume>:<fpage>724699</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2021.724699</pub-id><pub-id pub-id-type="pmid">34490270</pub-id><pub-id pub-id-type="pmcid">PMC8416509</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherrill</surname><given-names>DL</given-names></name><name name-style="western"><surname>Halonen</surname><given-names>M</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>B</given-names></name></person-group>. <article-title>Relationships between total serum IgE, atopy, and smoking: a twenty-year follow-up analysis</article-title>. <source>J Allergy Clin Immunol</source>. (<year>1994</year>) <volume>94</volume>(<issue>6 Pt 1</issue>):<fpage>954</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/0091-6749(94)90113-9</pub-id><pub-id pub-id-type="pmid">7798543</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janbazacyabar</surname><given-names>H</given-names></name><name name-style="western"><surname>van Bergenhenegouwen</surname><given-names>J</given-names></name><name name-style="western"><surname>Garssen</surname><given-names>J</given-names></name><name name-style="western"><surname>Leusink-Muis</surname><given-names>T</given-names></name><name name-style="western"><surname>van Ark</surname><given-names>I</given-names></name><name name-style="western"><surname>van Daal</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Prenatal and postnatal cigarette smoke exposure is associated with increased risk of exacerbated allergic airway immune responses: a preclinical mouse model</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>797376</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.797376</pub-id><pub-id pub-id-type="pmid">35003121</pub-id><pub-id pub-id-type="pmcid">PMC8732376</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name></person-group>. <article-title>Cotinine as a biomarker of environmental tobacco smoke exposure</article-title>. <source>Epidemiol Rev</source>. (<year>1996</year>) <volume>18</volume>(<issue>2</issue>):<fpage>188</fpage>&#8211;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.epirev.a017925</pub-id><pub-id pub-id-type="pmid">9021312</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Shen</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>YJ</given-names></name></person-group>. <article-title>Dose-dependent effect of cotinine-verified tobacco smoking on serum immunoglobulin E levels in Korean adult males</article-title>. <source>Nicotine Tob Res</source>. (<year>2019</year>) <volume>21</volume>(<issue>6</issue>):<fpage>813</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1093/ntr/ntx247</pub-id><pub-id pub-id-type="pmid">29126169</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name><name name-style="western"><surname>Choi</surname><given-names>IH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>TH</given-names></name></person-group>. <article-title>Association of cotinine-verified cigarette exposure with chronic rhinosinusitis in Korean adults</article-title>. <source>Int J Environ Res Public Health</source>. (<year>2020</year>) <volume>17</volume>(<issue>21</issue>):<fpage>8291</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph17218291</pub-id><pub-id pub-id-type="pmid">33182521</pub-id><pub-id pub-id-type="pmcid">PMC7665152</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>HVS</given-names></name><name name-style="western"><surname>Masri</surname><given-names>SC</given-names></name><name name-style="western"><surname>Abdallah</surname><given-names>MS</given-names></name><name name-style="western"><surname>Chang</surname><given-names>AM</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>MG</given-names></name><name name-style="western"><surname>Elgendy</surname><given-names>IY</given-names></name><etal/></person-group><article-title>2022 ACC/AHA key data elements and definitions for chest pain and acute myocardial infarction: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical data standards</article-title>. <source>J Am Coll Cardiol</source>. (<year>2022</year>) <volume>80</volume>(<issue>17</issue>):<fpage>1660</fpage>&#8211;<lpage>700</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2022.05.012</pub-id><pub-id pub-id-type="pmid">36055903</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><article-title>2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020</article-title>. <source>Diabetes Care</source>. (<year>2020</year>) <volume>43</volume>(<issue>Suppl 1</issue>):<fpage>S14</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.2337/dc20-S002</pub-id><pub-id pub-id-type="pmid">31862745</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chobanian</surname><given-names>AV</given-names></name><name name-style="western"><surname>Bakris</surname><given-names>GL</given-names></name><name name-style="western"><surname>Black</surname><given-names>HR</given-names></name><name name-style="western"><surname>Cushman</surname><given-names>WC</given-names></name><name name-style="western"><surname>Green</surname><given-names>LA</given-names></name><name name-style="western"><surname>Jr</surname><given-names>IJ</given-names></name><etal/></person-group><article-title>The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report</article-title>. <source>JAMA</source>. (<year>2003</year>) <volume>289</volume>(<issue>19</issue>):<fpage>2560</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1001/jama.289.19.2560</pub-id><pub-id pub-id-type="pmid">12748199</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grundy</surname><given-names>SM</given-names></name><name name-style="western"><surname>Stone</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>AL</given-names></name><name name-style="western"><surname>Beam</surname><given-names>C</given-names></name><name name-style="western"><surname>Birtcher</surname><given-names>KK</given-names></name><name name-style="western"><surname>Blumenthal</surname><given-names>RS</given-names></name><etal/></person-group><article-title>2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines</article-title>. <source>Circulation</source>. (<year>2019</year>) <volume>139</volume>(<issue>25</issue>):<fpage>e1046</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000000624</pub-id><pub-id pub-id-type="pmid">30565953</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lang</surname><given-names>RM</given-names></name><name name-style="western"><surname>Badano</surname><given-names>LP</given-names></name><name name-style="western"><surname>Mor-Avi</surname><given-names>V</given-names></name><name name-style="western"><surname>Afilalo</surname><given-names>J</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>A</given-names></name><name name-style="western"><surname>Ernande</surname><given-names>L</given-names></name><etal/></person-group><article-title>Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging</article-title>. <source>J Am Soc Echocardiogr</source>. (<year>2015</year>) <volume>28</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>39.e14</lpage>. <pub-id pub-id-type="doi">10.1016/j.echo.2014.10.003</pub-id><pub-id pub-id-type="pmid">25559473</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayes</surname><given-names>AF</given-names></name><name name-style="western"><surname>Preacher</surname><given-names>KJ</given-names></name></person-group>. <article-title>Statistical mediation analysis with a multicategorical independent variable</article-title>. <source>Br J Math Stat Psychol</source>. (<year>2014</year>) <volume>67</volume>(<issue>3</issue>):<fpage>451</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1111/bmsp.12028</pub-id><pub-id pub-id-type="pmid">24188158</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C</given-names></name><etal/></person-group><article-title>The relationship of serum antigen-specific and total immunoglobulin E with adult cardiovascular diseases</article-title>. <source>Int J Med Sci</source>. (<year>2018</year>) <volume>15</volume>(<issue>11</issue>):<fpage>1098</fpage>&#8211;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.7150/ijms.25857</pub-id><pub-id pub-id-type="pmid">30123046</pub-id><pub-id pub-id-type="pmcid">PMC6097256</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>X</given-names></name><name name-style="western"><surname>Anzai</surname><given-names>A</given-names></name><name name-style="western"><surname>Katsumata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Matsuhashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ito</surname><given-names>K</given-names></name><name name-style="western"><surname>Endo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction</article-title>. <source>J Mol Cell Cardiol</source>. (<year>2013</year>) <volume>62</volume>:<fpage>24</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2013.04.023</pub-id><pub-id pub-id-type="pmid">23644221</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussain</surname><given-names>MS</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>V</given-names></name></person-group>. <article-title>Smoking under hypoxic conditions: a potent environmental risk factor for inflammatory and autoimmune diseases</article-title>. <source>Mil Med Res</source>. (<year>2018</year>) <volume>5</volume>(<issue>1</issue>):<fpage>11</fpage>. <pub-id pub-id-type="doi">10.1186/s40779-018-0158-5</pub-id><pub-id pub-id-type="pmid">29598831</pub-id><pub-id pub-id-type="pmcid">PMC5877397</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burrows</surname><given-names>B</given-names></name><name name-style="western"><surname>Halonen</surname><given-names>M</given-names></name><name name-style="western"><surname>Lebowitz</surname><given-names>MD</given-names></name><name name-style="western"><surname>Knudson</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Barbee</surname><given-names>RA</given-names></name></person-group>. <article-title>The relationship of serum immunoglobulin E, allergy skin tests, and smoking to respiratory disorders</article-title>. <source>J Allergy Clin Immunol</source>. (<year>1982</year>) <volume>70</volume>(<issue>3</issue>):<fpage>199</fpage>&#8211;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1016/0091-6749(82)90042-2</pub-id><pub-id pub-id-type="pmid">7108071</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piaggeschi</surname><given-names>G</given-names></name><name name-style="western"><surname>Rolla</surname><given-names>S</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>N</given-names></name><name name-style="western"><surname>Brusa</surname><given-names>D</given-names></name><name name-style="western"><surname>Naccarati</surname><given-names>A</given-names></name><name name-style="western"><surname>Couvreur</surname><given-names>S</given-names></name><etal/></person-group><article-title>Immune trait shifts in association with tobacco smoking: a study in healthy women</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>637974</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.637974</pub-id><pub-id pub-id-type="pmid">33767708</pub-id><pub-id pub-id-type="pmcid">PMC7985448</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnson</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shoenfeld</surname><given-names>Y</given-names></name><name name-style="western"><surname>Amital</surname><given-names>H</given-names></name></person-group>. <article-title>Effects of tobacco smoke on immunity, inflammation and autoimmunity</article-title>. <source>J Autoimmun</source>. (<year>2010</year>) <volume>34</volume>(<issue>3</issue>):<fpage>J258</fpage>&#8211;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaut.2009.12.003</pub-id><pub-id pub-id-type="pmid">20042314</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bullone</surname><given-names>M</given-names></name><name name-style="western"><surname>Carriero</surname><given-names>V</given-names></name><name name-style="western"><surname>Bertolini</surname><given-names>F</given-names></name><name name-style="western"><surname>Folino</surname><given-names>A</given-names></name><name name-style="western"><surname>Mannelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Di Stefano</surname><given-names>A</given-names></name><etal/></person-group><article-title>Elevated serum IgE, oral corticosteroid dependence and IL-17/22 expression in highly neutrophilic asthma</article-title>. <source>Eur Respir J</source>. (<year>2019</year>) <volume>54</volume>(<issue>5</issue>):<fpage>1900068</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.00068-2019</pub-id><pub-id pub-id-type="pmid">31439682</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuo</surname><given-names>H</given-names></name><name name-style="western"><surname>Nyg&#229;rd</surname><given-names>O</given-names></name><name name-style="western"><surname>Vollset</surname><given-names>SE</given-names></name><name name-style="western"><surname>Ueland</surname><given-names>PM</given-names></name><name name-style="western"><surname>Ulvik</surname><given-names>A</given-names></name><name name-style="western"><surname>Midttun</surname><given-names>&#216;</given-names></name><etal/></person-group><article-title>Smoking, plasma cotinine and risk of atrial fibrillation: the hordaland health study</article-title>. <source>J Intern Med</source>. (<year>2018</year>) <volume>283</volume>(<issue>1</issue>):<fpage>73</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1111/joim.12689</pub-id><pub-id pub-id-type="pmid">28940460</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brunetti</surname><given-names>R</given-names></name><name name-style="western"><surname>Hicklin</surname><given-names>H</given-names></name><name name-style="western"><surname>Rackley</surname><given-names>J</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>MI</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>EZ</given-names></name></person-group>. <article-title>Serum cotinine and silent myocardial infarction in individuals free from cardiovascular disease</article-title>. <source>Am J Cardiol</source>. (<year>2019</year>) <volume>124</volume>(<issue>5</issue>):<fpage>666</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2019.05.064</pub-id><pub-id pub-id-type="pmid">31272704</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>BQ</given-names></name><name name-style="western"><surname>Sun</surname><given-names>YP</given-names></name><name name-style="western"><surname>Sievers</surname><given-names>RE</given-names></name><name name-style="western"><surname>Glantz</surname><given-names>SA</given-names></name><name name-style="western"><surname>Parmley</surname><given-names>WW</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>CL</given-names></name></person-group>. <article-title>Exposure to environmental tobacco smoke increases myocardial infarct size in rats</article-title>. <source>Circulation</source>. (<year>1994</year>) <volume>89</volume>(<issue>3</issue>):<fpage>1282</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.89.3.1282</pub-id><pub-id pub-id-type="pmid">8124817</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fagerberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Barregard</surname><given-names>L</given-names></name></person-group>. <article-title>Review of cadmium exposure and smoking-independent effects on atherosclerotic cardiovascular disease in the general population</article-title>. <source>J Intern Med</source>. (<year>2021</year>) <volume>290</volume>(<issue>6</issue>):<fpage>1153</fpage>&#8211;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1111/joim.13350</pub-id><pub-id pub-id-type="pmid">34157165</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>F&#246;rstermann</surname><given-names>U</given-names></name><name name-style="western"><surname>Xia</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name></person-group>. <article-title>Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis</article-title>. <source>Circ Res</source>. (<year>2017</year>) <volume>120</volume>(<issue>4</issue>):<fpage>713</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309326</pub-id><pub-id pub-id-type="pmid">28209797</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choudhry</surname><given-names>S</given-names></name><name name-style="western"><surname>Avila</surname><given-names>PC</given-names></name><name name-style="western"><surname>Nazario</surname><given-names>S</given-names></name><name name-style="western"><surname>Ung</surname><given-names>N</given-names></name><name name-style="western"><surname>Kho</surname><given-names>J</given-names></name><name name-style="western"><surname>Rodriguez-Santana</surname><given-names>JR</given-names></name><etal/></person-group><article-title>CD14 Tobacco gene-environment interaction modifies asthma severity and immunoglobulin E levels in latinos with asthma</article-title>. <source>Am J Respir Crit Care Med</source>. (<year>2005</year>) <volume>172</volume>(<issue>2</issue>):<fpage>173</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.200409-1232OC</pub-id><pub-id pub-id-type="pmid">15879416</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Br&#252;ggemann</surname><given-names>TR</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>P</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>LM</given-names></name><name name-style="western"><surname>Sato</surname><given-names>MN</given-names></name><name name-style="western"><surname>Martins</surname><given-names>MA</given-names></name><name name-style="western"><surname>Arantes-Costa</surname><given-names>FM</given-names></name></person-group>. <article-title>Cigarette smoke increases CD8&#945;(+) dendritic cells in an ovalbumin-induced airway inflammation</article-title>. <source>Front Immunol</source>. (<year>2017</year>) <volume>8</volume>:<fpage>718</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.00718</pub-id><pub-id pub-id-type="pmid">28670318</pub-id><pub-id pub-id-type="pmcid">PMC5472682</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsiantoulas</surname><given-names>D</given-names></name><name name-style="western"><surname>Bot</surname><given-names>I</given-names></name><name name-style="western"><surname>Ozsvar-Kozma</surname><given-names>M</given-names></name><name name-style="western"><surname>G&#246;derle</surname><given-names>L</given-names></name><name name-style="western"><surname>Perkmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Hartvigsen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Increased plasma IgE accelerate atherosclerosis in secreted IgM deficiency</article-title>. <source>Circ Res</source>. (<year>2017</year>) <volume>120</volume>(<issue>1</issue>):<fpage>78</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309606</pub-id><pub-id pub-id-type="pmid">27903567</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>HT</given-names></name><name name-style="western"><surname>Lin</surname><given-names>YS</given-names></name><name name-style="western"><surname>Ye</surname><given-names>QM</given-names></name><name name-style="western"><surname>Yang</surname><given-names>XN</given-names></name><name name-style="western"><surname>Zou</surname><given-names>XL</given-names></name><name name-style="western"><surname>Yang</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Airway inflammation and remodeling of cigarette smoking exposure ovalbumin-induced asthma is alleviated by CpG oligodeoxynucleotides via affecting dendritic cell-mediated Th17 polarization</article-title>. <source>Int Immunopharmacol</source>. (<year>2020</year>) <volume>82</volume>:<fpage>106361</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2020.106361</pub-id><pub-id pub-id-type="pmid">32135492</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ezzati</surname><given-names>M</given-names></name><name name-style="western"><surname>Henley</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Thun</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>AD</given-names></name></person-group>. <article-title>Role of smoking in global and regional cardiovascular mortality</article-title>. <source>Circulation</source>. (<year>2005</year>) <volume>112</volume>(<issue>4</issue>):<fpage>489</fpage>&#8211;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.521708</pub-id><pub-id pub-id-type="pmid">16027251</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Symons</surname><given-names>R</given-names></name><name name-style="western"><surname>Masci</surname><given-names>PG</given-names></name><name name-style="western"><surname>Francone</surname><given-names>M</given-names></name><name name-style="western"><surname>Claus</surname><given-names>P</given-names></name><name name-style="western"><surname>Barison</surname><given-names>A</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>I</given-names></name><etal/></person-group><article-title>Impact of active smoking on myocardial infarction severity in reperfused ST-segment elevation myocardial infarction patients: the smoker&#8217;s paradox revisited</article-title>. <source>Eur Heart J</source>. (<year>2016</year>) <volume>37</volume>(<issue>36</issue>):<fpage>2756</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehv738</pub-id><pub-id pub-id-type="pmid">26804461</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbash</surname><given-names>GI</given-names></name><name name-style="western"><surname>White</surname><given-names>HD</given-names></name><name name-style="western"><surname>Modan</surname><given-names>M</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>R</given-names></name><name name-style="western"><surname>Hampton</surname><given-names>JR</given-names></name><name name-style="western"><surname>Heikkila</surname><given-names>J</given-names></name><etal/></person-group><article-title>Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the international tissue plasminogen activator/streptokinase mortality trial</article-title>. <source>Circulation</source>. (<year>1993</year>) <volume>87</volume>(<issue>1</issue>):<fpage>53</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.87.1.53</pub-id><pub-id pub-id-type="pmid">8419024</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Cho</surname><given-names>KH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MC</given-names></name><name name-style="western"><surname>Sim</surname><given-names>DS</given-names></name><name name-style="western"><surname>Hong</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>Association between baseline smoking status and clinical outcomes following myocardial infarction</article-title>. <source>Front Cardiovasc Med</source>. (<year>2022</year>) <volume>9</volume>:<fpage>918033</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2022.918033</pub-id><pub-id pub-id-type="pmid">35935630</pub-id><pub-id pub-id-type="pmcid">PMC9354586</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>M</given-names></name><name name-style="western"><surname>Mintz</surname><given-names>GS</given-names></name><name name-style="western"><surname>G&#233;n&#233;reux</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>McAndrew</surname><given-names>T</given-names></name><name name-style="western"><surname>Redfors</surname><given-names>B</given-names></name><etal/></person-group><article-title>The smoker&#8217;s paradox revisited: a patient-level pooled analysis of 18 randomized controlled trials</article-title>. <source>JACC Cardiovascular Interventions</source>. (<year>2019</year>) <volume>12</volume>(<issue>19</issue>):<fpage>1941</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2019.06.034</pub-id><pub-id pub-id-type="pmid">31521646</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>J</given-names></name><name name-style="western"><surname>van Klaveren</surname><given-names>D</given-names></name><name name-style="western"><surname>Campos</surname><given-names>CM</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>DR</given-names></name><name name-style="western"><surname>Kappetein</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Smoking is associated with adverse clinical outcomes in patients undergoing revascularization with PCI or CABG: the SYNTAX trial at 5-year follow-up</article-title>. <source>J Am Coll Cardiol</source>. (<year>2015</year>) <volume>65</volume>(<issue>11</issue>):<fpage>1107</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2015.01.014</pub-id><pub-id pub-id-type="pmid">25790882</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Min</surname><given-names>KB</given-names></name><name name-style="western"><surname>Min</surname><given-names>JY</given-names></name></person-group>. <article-title>Risk of cardiovascular mortality in relation to increased total Serum IgE levels in older adults: a population-based cohort study</article-title>. <source>Int J Environ Res Public Health</source>. (<year>2019</year>) <volume>16</volume>(<issue>22</issue>):<fpage>4350</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph16224350</pub-id><pub-id pub-id-type="pmid">31703438</pub-id><pub-id pub-id-type="pmcid">PMC6888246</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langer</surname><given-names>RD</given-names></name><name name-style="western"><surname>Criqui</surname><given-names>MH</given-names></name><name name-style="western"><surname>Feigelson</surname><given-names>HS</given-names></name><name name-style="western"><surname>McCann</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Hamburger</surname><given-names>RN</given-names></name></person-group>. <article-title>Ige predicts future nonfatal myocardial infarction in men</article-title>. <source>J Clin Epidemiol</source>. (<year>1996</year>) <volume>49</volume>(<issue>2</issue>):<fpage>203</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/0895-4356(95)00548-X</pub-id><pub-id pub-id-type="pmid">8606321</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabatine</surname><given-names>MS</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>DA</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>CP</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>SA</given-names></name><name name-style="western"><surname>Demopoulos</surname><given-names>LA</given-names></name><name name-style="western"><surname>DiBattiste</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy- thrombolysis in myocardial infarction 18 trial)substudy</article-title>. <source>J Am Coll Cardiol</source>. (<year>2002</year>) <volume>40</volume>(<issue>10</issue>):<fpage>1761</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0735-1097(02)02484-1</pub-id><pub-id pub-id-type="pmid">12446059</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Stefano</surname><given-names>R</given-names></name><name name-style="western"><surname>Di Bello</surname><given-names>V</given-names></name><name name-style="western"><surname>Barsotti</surname><given-names>MC</given-names></name><name name-style="western"><surname>Grigoratos</surname><given-names>C</given-names></name><name name-style="western"><surname>Armani</surname><given-names>C</given-names></name><name name-style="western"><surname>Dell'Omodarme</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inflammatory markers and cardiac function in acute coronary syndrome: difference in ST-segment elevation myocardial infarction (STEMI) and in non-STEMI models</article-title>. <source>Biomed Pharmacother</source>. (<year>2009</year>) <volume>63</volume>(<issue>10</issue>):<fpage>773</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2009.06.004</pub-id><pub-id pub-id-type="pmid">19906505</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neumann</surname><given-names>JT</given-names></name><name name-style="western"><surname>Weimann</surname><given-names>J</given-names></name><name name-style="western"><surname>S&#246;rensen</surname><given-names>NA</given-names></name><name name-style="western"><surname>Hartikainen</surname><given-names>TS</given-names></name><name name-style="western"><surname>Haller</surname><given-names>PM</given-names></name><name name-style="western"><surname>Lehmacher</surname><given-names>J</given-names></name><etal/></person-group><article-title>A biomarker model to distinguish types of myocardial infarction and injury</article-title>. <source>J Am Coll Cardiol</source>. (<year>2021</year>) <volume>78</volume>(<issue>8</issue>):<fpage>781</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2021.06.027</pub-id><pub-id pub-id-type="pmid">34412811</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paolisso</surname><given-names>P</given-names></name><name name-style="western"><surname>Fo&#224;</surname><given-names>A</given-names></name><name name-style="western"><surname>Bergamaschi</surname><given-names>L</given-names></name><name name-style="western"><surname>Donati</surname><given-names>F</given-names></name><name name-style="western"><surname>Fabrizio</surname><given-names>M</given-names></name><name name-style="western"><surname>Chiti</surname><given-names>C</given-names></name><etal/></person-group><article-title>Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA</article-title>. <source>Cardiovasc Diabetol</source>. (<year>2021</year>) <volume>20</volume>(<issue>1</issue>):<fpage>33</fpage>. <pub-id pub-id-type="doi">10.1186/s12933-021-01222-9</pub-id><pub-id pub-id-type="pmid">33530978</pub-id><pub-id pub-id-type="pmcid">PMC7856791</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>